Nyxoah (NYXH) Expected to Release Earnings on Wednesday

Nyxoah (NASDAQ:NYXH) is projected to post its Q2 2026 results before the market opens on Wednesday, August 5th. Analysts expect Nyxoah to announce earnings of ($0.47) per share and revenue of $8.6370 million for the quarter. Interested persons may review the information on the company’s upcoming Q2 2026 earning report for the latest details on the call scheduled for Wednesday, August 5, 2026 at 4:30 PM ET.

Nyxoah (NASDAQ:NYXH) last posted its quarterly earnings data on Tuesday, May 12th. The company reported ($0.43) EPS for the quarter, topping analysts’ consensus estimates of ($0.54) by $0.11. Nyxoah had a negative return on equity of 163.73% and a negative net margin of 543.21%.The firm had revenue of $7.38 million during the quarter, compared to analysts’ expectations of $7.05 million. On average, analysts expect Nyxoah to post $-2 EPS for the current fiscal year and $-1 EPS for the next fiscal year.

Nyxoah Trading Up 2.1%

Shares of NYXH stock opened at $1.43 on Wednesday. The company has a market capitalization of $55.43 million, a price-to-earnings ratio of -0.58 and a beta of 1.61. The company has a current ratio of 0.99, a quick ratio of 0.88 and a debt-to-equity ratio of 0.53. The firm has a 50-day moving average price of $1.89 and a 200 day moving average price of $3.14. Nyxoah has a twelve month low of $1.26 and a twelve month high of $8.59.

Analyst Ratings Changes

A number of equities research analysts have recently commented on NYXH shares. Stifel Nicolaus lowered their price target on shares of Nyxoah from $5.00 to $3.00 and set a “hold” rating for the company in a report on Wednesday, June 17th. Piper Sandler reissued an “overweight” rating and set a $7.00 price objective (down from $9.00) on shares of Nyxoah in a research note on Wednesday, May 13th. Robert W. Baird set a $2.85 target price on shares of Nyxoah in a research report on Thursday, July 9th. Finally, Weiss Ratings cut shares of Nyxoah from a “sell (d-)” rating to a “sell (e+)” rating in a research note on Friday, May 22nd. Two equities research analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat, the stock has a consensus rating of “Hold” and an average target price of $5.96.

Institutional Trading of Nyxoah

Several institutional investors have recently made changes to their positions in NYXH. Raymond James Financial Inc. increased its holdings in shares of Nyxoah by 35.6% during the 3rd quarter. Raymond James Financial Inc. now owns 12,762 shares of the company’s stock worth $59,000 after buying an additional 3,353 shares during the last quarter. Bank of America Corp DE grew its position in Nyxoah by 72.4% during the second quarter. Bank of America Corp DE now owns 7,866 shares of the company’s stock valued at $59,000 after acquiring an additional 3,303 shares during the period. Citadel Advisors LLC purchased a new stake in Nyxoah during the third quarter valued at about $98,000. Deutsche Bank AG grew its position in Nyxoah by 40.0% during the fourth quarter. Deutsche Bank AG now owns 35,000 shares of the company’s stock valued at $161,000 after acquiring an additional 10,000 shares during the period. Finally, Shay Capital LLC acquired a new stake in Nyxoah during the second quarter worth about $374,000.

Nyxoah Company Profile

Nyxoah SA, headquartered in Mont-Saint-Guibert, Belgium, is a medical technology company focused on neuromodulation therapies for sleep‐disordered breathing. Established in 2018, the company’s primary offering is the Genio® system, a minimally invasive bilateral hypoglossal nerve stimulator designed to treat moderate to severe obstructive sleep apnea (OSA). By electrically stimulating the genioglossus muscle, the device helps maintain airway patency during sleep, reducing apnea events and improving overall sleep quality.

The Genio system comprises a small, implantable stimulator positioned submentally and an external activation unit worn by the patient.